---
schema_version: "secwatch.filing_event.v1"
accession: "0001297184-25-000003"
form_type: "8-K"
ticker: "AMPH"
cik: "0001297184"
company_name: "Amphastar Pharmaceuticals, Inc."
filed_at: "2025-02-27T23:59:59+00:00"
generated_at: "2026-05-26T01:10:53.759353+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Amphastar Q4 net revenue $186.5M, adj EPS $0.92; FY $732M, adj EPS $3.86

## Summary
- Q4 net revenue $186.5M, up 4.7% YoY; GAAP net income $38.0M ($0.74 per share).
- FY 2024 net revenue $732.0M, up 13.6% YoY; GAAP net income $159.5M ($3.06 per share).
- Adjusted non-GAAP net income Q4 $47.2M ($0.92 per share); FY $200.8M ($3.86 per share).
- Primatene MIST exceeded $100M annual sales in 2024; BAQSIMI factory sales grew 12% vs Q4 2023.
- CEO cites progress on proprietary pipeline for 2025.

## SEC filing metadata
- accession: 0001297184-25-000003
- form_type: 8-K
- ticker: AMPH
- cik: 0001297184
- company_name: Amphastar Pharmaceuticals, Inc.
- filed_at: 2025-02-27T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1297184/000129718425000003/0001297184-25-000003-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1297184/000129718425000003/amph-20250227x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001297184-25-000003
- JSON: https://secwatch.observer/filing/0001297184-25-000003.json
- Plain text: https://secwatch.observer/filing/0001297184-25-000003.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.